All In Biotech

Drug Trial Radar · NCT02946463

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Last checked: Nov 20, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

272

Actual

Start

Dec 12, 2016

Primary completion

Feb 28, 2023

Study completion Feb 28, 2023

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

  • RavulizumabBiological

    All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.

  • EculizumabBiological

    All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) LevelsTime frame: Day 29 through Day 183
  2. Percentage Of Participants Who Achieved Transfusion Avoidance (TA)Time frame: Baseline through Day 183

Locations

120 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Whittier, California

  • Research Site

    Fort Worth, Texas

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Perth, Australia

  • Research Site

    Linz, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Brussels, Belgium

  • Research Site

    Hasselt, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Pilsen, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Tallinn, Estonia

  • Research Site

    Limoges, France

  • Research Site

    Montpellier, France

  • Research Site

    Paris, France

  • Research Site

    Pierre-Bénite, France

  • Research Site

    Poitiers, France

  • Research Site

    Rennes, France

  • Research Site

    Aachen, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Ulm, Germany

  • Research Site

    Ascoli Piceno, Italy

  • Research Site

    Florence, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Vicenza, Italy

  • Research Site

    Bunkyō City, Japan

  • Research Site

    Bunkyō City, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Fukushima, Japan

  • Research Site

    Hamamatsu, Japan

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.